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In patients with acute pulmonary embolism (APE), a novel catheter-directed treatment technology, EkoSonic® Endovascular System 
(EKOS) is reported to facilitate the thrombolysis with a reduced bleeding risk.
This single-center study based on the retrospective evaluation of the 44 patients with documented APE (female 21, mean age 57+15.9 
years) at intermediate-high risk (n= 33) or high risk (n=11) who underwent EKOS treatment. The mean time delay from symptoms to 
treatment was 8.9+5.7 days. The mean dose of recombinant tissue-plasminogen activator ( t-PA) and duration of t-PA infusion were 
24.1+11.4 mg and 18.9+6.8 hours, respectively. Pre and post-procedural pulmonary artery (PA) systolic and mean pressures (mmHg) 
were 52.2±16.9 vs 40.8 ±15.5 and 27.8 ± 9.9 vs 22.6 ± 8.9, respectively (p<0.0001). PA trombus burden as quantified by Qanadli score 
(QS) (25.3 ± 6.07 vs 12.3 ± 4.3), right ventricle to left ventricle diameter ratio(RV/LV) (1.2 ± 0.2 vs 0.91± 0.10) and right atrial to left 
atrial diameter ratio(RA/LA) (1.35 ± 0.28 vs 1.1± 0.20) as assessed by computed tomography and tricuspid annular planary excursion 
(TAPSE) (mm)(12.4 ± 3.2 vs 13.25 ± 2.8) assessed by Echocardiography, were significantly improved after EKOS (p < 0.0001 for all). 
The quantitative benefit in these measures were comparable between high risk and intermediate-high risk groups (p=NS). The significant 
correlations were noted among the improvements in the QS, PA pressures, RV/LV diameter ratio and RA/LA diameter ratio (r = 0.47 to 
0.90, p < 0.05 to 0.0001). One patient with hypoxemia and severe RV dysfunction due to complete obstruction of right PA died at 12th 
hour of t-PA infusion. In other 43 patients, utilization of EKOS system was not associated with major bleeding, APE-related morbidity and 
mortality during in-hospital period or post-discharge follow-up period of 194.9 + 171.9 days.
In summary, low-dose t-PA administrated with EKOS system facilitates the resolution of PA thrombus burden, restoration of the pulmonary 
hemodynamics and right-sided cardiac functions without major procedure-related complications in majority of the patients with APE 
regardless of the high or intermediate-high risk status.
